The pharmaceutical industry is experiencing great change. Despite the number of merger and acquisitions (M&A) having steadily declined since the global financial crisis, the total value of chemicals and pharmaceutical deals has increased. In 2014 alone, the market saw $162 billion worth of deals inked, largely underpinned by large pharmaceutical deals. M&A transactions in biotech and pharmaceutical industry in the first two months of 2015 reached $59.3 billion, a 94% increase over the same period a year ago.